The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential
Miriam Verdú-Bou(Josep Carreras Leukaemia Research Institute), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Manel Esteller(Institució Catalana de Recerca i Estudis Avançats), Antonio Salar(Hospital Del Mar), Fina Climent, Annette M. Staiger(Robert Bosch Hospital), Mariana Bastos‐Oreiro(Hospital General Universitario Gregorio Marañón), José Luís Mate(Universitat Autònoma de Barcelona), Javier Menárguez, Gaël Roué(Josep Carreras Leukaemia Research Institute), Georg Lenz(Charité - Universitätsmedizin Berlin), Marcelo Lima Ribeiro(Universidade São Francisco), Miguel Alcoceba(Instituto de Investigación Biomédica de Salamanca), Eva González‐Barca(Institut Català d'Oncologia), Aleix Méndez López(Institut Català d'Oncologia), Fabian Frontzek(Spinal Cord Injury BC), German Ott(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Gustavo Tapia(Hospital Universitari Germans Trias i Pujol), Juan‐Manuel Sancho(Hospital Universitari Germans Trias i Pujol), Josep Castellví(Universitat Autònoma de Barcelona), Ioannis Anagnostopoulos(Humboldt-Universität zu Berlin), Núria Profitós-Pelejà(Josep Carreras Leukaemia Research Institute), Maria João Baptista(Josep Carreras Leukaemia Research Institute), Pau Abrisqueta(Universitat Autònoma de Barcelona)
Cited by 5
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Inactivation of the DNA-Repair Gene<i>MGMT</i>and the Clinical Response of Gliomas to Alkylating Agents
|New England Journal of Medicine|2000|2.2k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k